Safe administration of sotrovimab to a COVID-19 patient with acute phase type 1 diabetes mellitus

Type 1 diabetes mellitus (T1DM) and poor glycemic control are risk factors for severe coronavirus disease 2019 (COVID-19). Sotrovimab can treat mild-to-moderate COVID-19 in patients at a high risk of progression to severe COVID-19. However, its safety and efficacy in T1DM patients remain to be eluci...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Haruna, Matsumoto, Masaaki, Hong, Sung Won, Mitsuboshi, Akari, Nagai, Masashi, Yoshino, Go, Otake, Shogo, Matsuo, Susumu, Yamada, Hiroyuki, Kurosawa, Hiroshi, Kasai, Masashi, Ozaki, Kayo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society for Pediatric Endocrinology 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068621/
https://www.ncbi.nlm.nih.gov/pubmed/37020700
http://dx.doi.org/10.1297/cpe.2022-0077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068621/
https://www.ncbi.nlm.nih.gov/pubmed/37020700
http://dx.doi.org/10.1297/cpe.2022-0077

Ejemplares similares